Skip to main content
. Author manuscript; available in PMC: 2024 Mar 15.
Published in final edited form as: Clin Cancer Res. 2023 Sep 15;29(18):3573–3578. doi: 10.1158/1078-0432.CCR-23-0459

Table 2: Efficacy Results in Patients with RET Fusion-Positive Solid Tumors in Study LIBRETTO-001.

RETEVMO (n = 41)
Overall Response Rate1 (95% CI) 44% (28, 60)
 Complete response 4.9%
 Partial response 39%
Duration of Response
 Median in months (95% CI) 24.5 (9.2, NE)
 % with ≥6 months2 67%
1

Confirmed overall response rate assessed by BIRC.

2

Based on observed duration of response.

NE = not estimable

Source: U.S. product labeling, RETEVMO (selpercatinib)5